Inlyta
Inlyta ingredients
| Active ingredient | Strength |
|---|---|
| Axitinib | 5 mg/1, 1 mg/1 |
What Inlyta is used for
The FDA lists the approved uses on the official label (below). In the EU, axitinib is approved as Inlyta for:
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Inlyta
- Generic name
- Axitinib
- Made by
- Pfizer Laboratories Div Pfizer Inc
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA202324
- On the US market since
- 2012
Official information
- Inlyta prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Axitinib)
In India
- Axitinib: 14 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Inlyta?
Inlyta (Axitinib) is a cancer medicine made by Pfizer Laboratories Div Pfizer Inc, approved by the US FDA.
What are the ingredients of Inlyta?
Inlyta contains Axitinib (5 mg/1, 1 mg/1).
Is Inlyta approved in Europe?
The same active substance is approved in the EU as Inlyta.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA